(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
4 Masked Men Steal Renoir, Matisse and Cézanne Paintings Worth Over $10 Million in 3-Minute Heist- Figure out How to Introduce Sunlight powered chargers on Your Rooftop securely
- What you need to know about desalination, a growing source of drinking water
- Would you ever turn to AI for companionship? 6% of Americans say they could — or already have.
- Manual for Mountain Objections on the planet
- Former GLP-1 users regain lost weight after about 18 months, study says
- Dental, Vision, and Hearing Inclusion in Senior Protection.
- Prehistoric wolf’s gut frozen in time reveals an ice age giant
- I asked ChatGPT who would win a Golden Globes. Here's what it got right — and totally wrong.
